Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Randomized controlled trials are being discussed
An occupational exposure limit (OEL) approach to protect home healthcare workers exposed to common nebulized drugs
An oral option for obesity could expand the addressable population
Product information: OZEMPIC(R) subcutaneous injection, semaglutide subcutaneous injection
The ACCORD trial found that intensive glucose-lowering therapies were associated with increased all-cause mortality in patients with a history of cardiovascular disease, underscoring the importance of cautious titration [40]
doi: 10.1111/dme.14050 71 Hasan AliOBernerFBomzeDFasslerMDiemSCozzioAet al
US$ 28.34
US$ 24.46
US$ 25.68
US$ 26.49
